Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review

Nadia N. Ahmad | Susan Robinson | Tessa Kennedy-Martin | Jiat Ling Poon | Hong Kan

Summary

Anti-obesity medications (AOMs) are efficacious and well tolerated in randomized controlled trials, but findings may not be generalizable to routine clinical practice. This systematic literature review aimed to identify real-world (RW) evidence for AOMs to treat adults (≥18 years) with obesity or overweight (BMI ≥ 27 kg/m²). Searches conducted in MEDLINE, Embase, Health Technology Assessment (HTA) Database, National Health Service (NHS) Economic Evaluation Database, and Cochrane Central Register of Controlled Trials for studies of relevant FDA-approved AOMs yielded 41 publications. Weight loss (WL) was consistently observed, with 14% to 58.6% of patients achieving ≥5% WL on orlistat, phentermine/topiramate, naltrexone/bupropion, phentermine, or liraglutide in studies of 3–6 months’ duration where this was measured. When cardiometabolic risk factors were assessed, AOMs reduced or had no impact on blood pressure, lipids, or glycemia. RW data on the impact of AOMs on existing obesity-related comorbidities and mortality were generally lacking. AOMs were associated with various adverse events, but these were of mild to moderate severity and no unexpected safety signals were reported. A pattern of poor adherence and persistence with AOMs was observed across studies. Overall, the review confirmed the effectiveness of AOMs in RW settings but demonstrated large gaps in the evidence base.

Keywords

anti-obesity medication, effectiveness

Abbreviations:
AE, adverse event; AERS, adverse event reporting system; ALT, alanine transaminase; AOM, anti-obesity medication; BMI, body mass index; BPN, bupropion; CEA, cost-effectiveness analysis; CI, confidence interval; CPRD, Clinical Practice Research Database; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; EMR, electronic medical records; FBG, fasting blood glucose; FDA, Food and Drug Administration; FEN, fenfluramine; HbA₁c, glycated hemoglobin; HCRU, healthcare resource utilization; HDL-C, high-density lipoprotein cholesterol; HMO, Health Management Organization; HR, heart rate; HRQoL, health-related quality of life; hsCRP, high-sensitivity C-reactive protein; HTA, Health Technology Assessment; IQR, interquartile range; LAGB, laparoscopic-adjustable gastric band; LDL-C, low-density lipoprotein cholesterol; LIRA, liraglutide; LORC, lorcaserin; MACE, major adverse cardiovascular event; MI, myocardial infarction; MPR, medication possession ratio; NHS, National Health Service; NTX, naltrexone; OECD, Organisation for Economic Co-operation and Development; OR, odds ratio; ORL, orlistat; PCMH, patient-centered medical home; PDC, proportion of days covered; PHEN, phentermine; PORTAL, Patient Outcomes Research to Advance Learning; PRO, patient-reported outcome; PSM, propensity score matched; RCT, randomized controlled trial; RW, real-world; RWE, real-world evidence; RYGB, Roux-en-Y gastric bypass; SAE, serious adverse event; SBP, systolic blood pressure; SG, sleeve gastrectomy; SIB, sibutramine; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglycerides; TPM, topiramate; VA, Veteran’s Affairs; VLED, very-low energy diet; WL, weight loss.
1 | INTRODUCTION

Obesity is a major public health issue with a prevalence that has tripled over the last 45 years.\(^1\) In 2015, it was estimated that nearly 604 million adults (12%) worldwide were classified as having obesity (body mass index [BMI] ≥ 30 kg/m\(^2\)).\(^2\) Furthermore, in an analysis of the 2015 Global Burden of Disease study, high BMI was reported to account for 4 million deaths globally and to contribute to 120 million disability-adjusted life years.\(^3\) Obesity also imposes a considerable economic burden on healthcare systems and society,\(^4\) primarily driven by the treatment of obesity-related chronic diseases as well as presenteeism, absenteeism, and reduced employment rates.\(^5\) For example, in the United States, individuals with obesity had annual healthcare costs US $3500 higher than individuals without obesity, resulting in a national cost of US$316 billion per year or 27.5% of US healthcare spending in 2010.\(^6\) Similarly, international data from 52 Organisation for Economic Co-operation and Development (OECD) countries suggests that over the next 30 years, overweight and obesity will cost US$425 billion per year, representing 8.4% of total global healthcare spending.\(^7\)

Prevention of obesity through policy changes and healthy lifestyle promotion is critical to curb the worsening epidemic. However, with such high proportions of individuals already manifesting obesity, there is also a pressing need for treatment. A stepwise approach to obesity treatment is generally advocated involving initial lifestyle interventions followed by pharmacologic intervention and bariatric surgery, if necessary. Lifestyle-based therapies represent the cornerstone of obesity management, but alone do not provide sustainable weight loss in most individuals,\(^8\) and bariatric surgery, though highly effective, is applied in only a minority of eligible cases.\(^9\) As such, there is an urgent need for well-tolerated and effective pharmacologic anti-obesity therapy. Currently, five anti-obesity medications (AOMs; liraglutide, semaglutide, phentermine/topiramate [PHEN/TPM], naltrexone/bupropion [NTX/BPN], and orlistat) are approved for long-term use by the US Food and Drug Administration (FDA) for the treatment of adults with a BMI ≥ 30 or ≥ 27 kg/m\(^2\) with at least one weight-related comorbidity, and several other medications are in clinical development.\(^10\) Furthermore, another four treatments (phentermine, benzphetamine, diethylpropion, and phendimetrazine) are FDA approved for short-term (a few weeks) use, although with the exception of phentermine these are rarely utilized in real-world settings.\(^11\)

The efficacy and safety of AOMs have been well documented in randomized controlled trials (RCTs). A systematic literature review including 35 RCTs reported that the AOMs FDA-approved for long-term use at the time were all associated with greater weight loss and weight-loss maintenance compared with placebo and were associated with generally low rates of serious adverse events (SAEs).\(^12\) However, the effectiveness of AOMs in real-world practice is not as well understood. Unlike RCTs, real-world studies include heterogeneous patient samples that are more representative of the general disease population likely to be treated by primary care and specialist physicians. Real-world studies can support data from RCTs and provide more information on clinical outcomes, safety signals, patient persistence and adherence, economic outcomes, and longer-term treatment trends, all of which are fundamental in informing disease management practices and healthcare policy.\(^13\)

The objective of the current review was, therefore, to identify, summarize, and interpret retrospective or prospective published studies that provide real-world evidence (RWE) for AOMs in the treatment of adults (≥ 18 years) with obesity or overweight. While the original search comprised a broad focus, this manuscript is limited to a summary of weight change, cardiometabolic risk factors, adverse events (AEs), and adherence, persistence, and discontinuation, since these were the most commonly and consistently reported measures.

2 | METHODS

A robust and reproducible protocol for the literature search was developed that detailed the proposed approach, objectives, search strategy, study selection criteria, methods for data extraction and synthesis, and outcomes of interest that were specified a priori. The protocol reduced the potential impact of review author bias, ensured transparency and accountability, and maximized the chances of accurate data extraction.

2.1 | Search strategy

MEDLINE, Embase, the Health Technology Assessment (HTA) Database, the National Health Service (NHS) Economic Evaluation Database, and the Cochrane Central Register of Controlled Trials were searched to identify relevant studies. Searches were run in October 2019 with no date limit. A hand search of the bibliographies of eligible publications was also undertaken to identify any relevant studies that were not found by the original search.

The overall search strategy comprised three concepts: “weight loss” AND “specific AOMs of interest” AND “RWE.” Notably, the more general concept of “AOMs” without mention of specific drugs of interest was not a part of the search strategy as the aim was to only identify and include studies in which drug-level data for the specific AOMs of interest were presented. Concepts were captured using subject headings and text-word searches in the title, abstract, and keyword-heading fields. A base-case strategy was developed for MEDLINE and adapted to the other databases (Tables S1–S5); additional details regarding the search strategy can be found in the Supporting Information.

2.2 | Eligibility criteria

The search eligibility criteria are shown in Table 1. While the original search included a range of AOMs, only those that were FDA-approved for long-term use at the time of the search are the focus of the current article. Publications that evaluated outcomes associated with lorcaserin and sibutramine are not summarized here, but where evaluated as comparators in the included studies, findings were noted. Of the AOMs...
TABLE 1  Study selection criteria

| Study characteristic | Eligibility criteria |
|----------------------|---------------------|
| Patient population   | Adults (age ≥ 18 years) with overweight or obesity |
| AOM                  | Orlistat, Lorcaserin hydrochloride, Phentermine, Phentermine–topiramate, Naltrexone–bupropion, Liraglutide, Sibutramine |
| Comparator           | All interventions including placebo or usual care and other AOMs, Baseline (before/after comparison), No comparator |
| Outcomes b           | Weight change (BMI, total fat mass, visceral fat mass, weight, waist circumference, waist/hip ratio), Cardiometabolic risk factors (lipids, hsCRP, ALT, SBP, DBP, HbA1c, FBG, fasting insulin), Incidence of obesity-related comorbidities, Change in existing comorbidity, Adverse events, Economic outcomes (costs, healthcare resource utilization), Patient-reported outcomes (HRQoL, patient preference, patient satisfaction, functioning/activities of daily living, pain and discomfort), Adherence, persistence, discontinuation, reasons for discontinuation |
| Study type           | RW cross-sectional, RW case–control, RW cohort, Pragmatic clinical trials, Administrative or claims database, Electronic medical records, Registry representing RW practice, Questionnaires and surveys relating to RW practice |
| Language             | English |

Abbreviations: ALT, alanine transaminase; AOM, anti-obesity medication; BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HCRU, healthcare resource utilization; HRQoL, health-related quality of life; hsCRP, high-sensitivity C-reactive protein; RW, real-world; SBP, systolic blood pressure.

aSibutramine and lorcaserin are not FDA-approved but were included in the broad search; studies including only data related to these drugs were excluded from the review.

bOnly most commonly and consistently reported outcomes described in the review; for example, economic outcomes and patient-reported outcomes were rarely included and so findings are not reported in this review.

FDA-approved for short-term use, only phentermine was included as it is one of the most frequently prescribed in real-world practice.10

2.3 | Study selection process

Search results were assessed independently by two reviewers, using a two-phase approach that consisted of (1) a broad review of the title and/or abstract of search results and (2) a subsequent full-text review of potentially eligible studies identified at Stage 1. Any studies failing to meet the selection criteria at Stage 2 were excluded and the reason for exclusion recorded. Any disagreements between reviewers were resolved by discussion until consensus was met.

Data extraction was performed on a standardized data extraction form by two reviewers, with quality checking by a third. Variables extracted included study population, interventions, study type and methods (including data source), study duration, and specific outcomes data.

3 | RESULTS

The search identified 2613 studies for eligibility review after removal of duplicates, of which 2535 were excluded following review of titles and abstracts. Of 78 full-text records, 35 were excluded (Figure 1). An additional two studies were identified by citation searching of included records to yield a total of 45 studies. Four of these studies evaluated sibutramine alone and so were also excluded, leaving 41 eligible studies for inclusion in the review.

3.1 | Study characteristics

Table 2 provides an overview of the characteristics of included studies. Studies were conducted across a wide geography, with the United States and the United Kingdom being the most represented countries.

3.1.1 | Study designs

Most studies were of a retrospective design (n = 33), and data were mostly collected from medical records and charts (electronic or otherwise). Other data sources utilized in retrospective studies included administrative claims databases, pharmacy prescription data, and AE reporting systems. Only eight studies were prospective in design, with data mostly obtained at prespecified clinic visits. Studies were conducted specifically in primary (n = 12) and secondary/tertiary care settings such as specialist clinics, academic centers, and hospitals (n = 16), with 13 studies including data from both settings. In most studies, outcomes associated with AOMs were compared with baseline (pre-drug) measures. Few studies included direct comparisons between different AOMs and even fewer a direct comparison of AOMs with diet and lifestyle modifications.

3.1.2 | Adjunctive measures

As AOMs are recommended as an adjunct to diet and exercise, lifestyle-based therapies were described in approximately half of studies, although the level of detail varied widely. Measures generally included counseling and education with respect to diet and lifestyle
changes and/or participation in weight-loss clinics or programs. In some studies, diet and lifestyle interventions preceded AOM use, while in others lifestyle intervention was delivered together with AOMs. Compliance with such measures was seldom captured.

### 3.1.3 | Study populations

A general population of individuals with obesity or overweight was evaluated in most studies. Three studies included patients with obesity and diabetes mellitus (predominantly type 2 diabetes mellitus [T2DM]).\(^{16,24,34}\) Weight outcomes were also evaluated in subgroup analyses in individuals with T2DM or cardiovascular disease (CVD) in two further studies.\(^{30,47}\) A single study evaluated elderly patients with obesity.\(^{38}\)

Several studies were also identified that included surgical patients who had undergone a variety of bariatric procedures including Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), laparoscopic adjustable gastric band (LAGB), and vertical banded gastroplasty.\(^{19,20,49-52}\) Patients in these studies received AOMs if they had regained weight from their postsurgical nadir weight or experienced inadequate initial weight loss following bariatric surgery. One study specifically included a younger (21–30 years) postsurgical population,\(^{53}\) and one included a subgroup analysis in patients with T2DM.\(^{51}\)

### 3.1.4 | Study drugs and outcomes evaluated

Orlistat was the most evaluated AOM across studies (\(n = 21\)), followed by phentermine (\(n = 14\)), PHEN/TPM (\(n = 7\)), liraglutide
| Author (country) | Study type/patient population | Healthcare setting | Data source | Baseline characteristics of study population | Study drugs, n |
|-----------------|-------------------------------|--------------------|-------------|---------------------------------------------|---------------|
| **PROSPECTIVE STUDIES** | | | | | |
| Hayes et al. (UK) | Prospective | P | EMR (CPRD) | Age, years (mean or median): 46.1 | BMI: 36.4 | ORL, n = 77,047 |
| Hollywood and Ogden (UK) | Prospective | P | Questionnaire (Xenical Support System) | Male, %: 17.5 | BMI: 36.2 | ORL, n = 566 |
| Kim et al. (Korea) | Prospective | P | Clinic visits (multicenter) | BMI: 31.5; F, 26.8; Weight: M, 94.2; F, 67.8 | PHEN, n = 795 |
| Rowe et al. (UK) | Prospective, DM | S | Clinic visit (single center) | BMI: 39.5 | Weight: M, 126.2; F, 98.1 | ORL, n = 100 |
| Schwartz et al. (USA) | Prospective | P, S | Pharmacy visits/telephone interview | BMI: 32.0 | Weight: 88.6 | ORL, n = 237 |
| Wirth (Germany) | Prospective | P | Clinic visits (multicenter) | BMI: 34.7 | Weight: 99.2 | ORL, n = 15,549 (alone + adjunctive measures) |
| **PROSPECTIVE STUDIES INCLUDING POSTSURGICAL PATIENTS** | | | | | |
| Suliman et al. (UAE) | Prospective, surgical and non-surgical | S | Clinic visits (single center) | BMI: 37.5 | Weight: 97.9 | LIRA, n = 787 (surgical, n = 76; non-surgical, n = 711) |
| Wharton et al. (Canada) | Prospective, surgical | S | Clinic visits (single center) | BMI: 42.5 | ORL, n = 117 |
| ** RETROSPECTIVE STUDIES** | | | | | |
| Aagaard et al. (Europe) | Retrospective | P, S | AERS | Age, years (mean or median): > 18 y, 98% | BMI: 30.6 | Weight: 79.3 | ORL, n = 1710d |
| Acharya et al. (UK) | Retrospective | P | Prescription data | Male, %: 15 | BMI: 40 | Weight: 116 | ORL, n = 16,021 |
| Ahn et al. (Korea) | Retrospective | S | Medical records (single center) | BMI: 30.6 | Weight: 79.3 | ORL, n = 63 |
| Allie et al. (USA) | Retrospective, T2DM | S | EMR (single center) | BMI: 35.0 | Weight: 99.3 | ORL after ≥ 2.5 kg, n = 156 or < 2.5 kg diet weight loss, n = 107 |
| Beermann et al. (Sweden) | Retrospective | P, S | Postal questionnaire | BMI: 35.0 | Weight: 99.3 | ORL, n = 626 |
| Aagaard et al. (Europe) | Retrospective | P, S | AERS | Age, years (mean or median): > 18 y, 98% | BMI: 30.6 | Weight: 79.3 | ORL, n = 1710d |
| Acharya et al. (UK) | Retrospective | P | Prescription data | Male, %: 15 | BMI: 40 | Weight: 116 | ORL, n = 16,021 |
| Ahn et al. (Korea) | Retrospective | S | Medical records (single center) | BMI: 30.6 | Weight: 79.3 | ORL, n = 63 |
| Allie et al. (USA) | Retrospective, T2DM | S | EMR (single center) | BMI: 35.0 | Weight: 99.3 | ORL after ≥ 2.5 kg, n = 156 or < 2.5 kg diet weight loss, n = 107 |
| Author (country) | Study type/patient population | Healthcare setting$^a$ | Data source | Baseline characteristics of study population$^b$ |
|-----------------|-------------------------------|------------------------|-------------|--------------------------------------------------|
|                 |                               |                        |             | Age, years (mean or median) | Male, % | BMI, kg/m² | weight, kg | Study drug(s), n |
| Costello et al. (USA)$^{26}$ | Retrospective | P | EMR (PCMH model) | 34 | 7.4 | BMI: 40.7 | Weight: 113.6 | PHEN, n = 22 | PHEN/TPM, n = 5 |
| Czernichow et al. (The Netherlands)$^{27}$ | Retrospective | P, S | Registry (pharmacy data) | 46.5 | 21.3 | ORL, n = 6139 |
| Derby et al. (UK)$^{28}$ | Retrospective | P | EMR (CPRD) | 48.4 | 31.3 | ORL, n = 988 |
| Douglas et al. (UK)$^{29}$ | Retrospective | P | EMR (CPRD) | 46.2 | 23.6 | ORL, n = 100,701 | SIB, n = 15,355 |
| Douglas et al. (UK)$^{29}$ | Retrospective | P | EMR (CPRD) | 46.2 | 23.6 | ORL, n = 100,701 | SIB, n = 15,355 |
| Ganguly et al. (USA)$^{31}$ | Retrospective | P, S | Claims data (Truven Health) | 46.7–48.5 | 17.8–27.6 | ORL, n = 4083 | NTX/BPN, n = 11,660 | PHEN/TPM, n = 4195 | LORC, n = 6584 |
| Gorgojo-Martinez et al. (Spain)$^{32}$ | Retrospective | S | EMR (single center) | ORL, 47.3 | LIRA, 51.9 | ORL, 25 | LIRA, 27 | ORL, BMI: 41.4; weight: 107.8 | LIR, 27; weight: 105.1 | ORL, n = 400 | LIRA, n = 100 |
| Grabarzyk (USA)$^{33}$ | Retrospective | P, S | EMR (VA Corporate Data Warehouse) | 52.4–58.4 | 62.5–76.5 | BMI: 39.5–41.5 | Weight: 121.1–128.0 | ORL, n = 6153 | LORC, n = 298 | PHEN, n = 304 | PHEN/TPM, n = 233 |
| Graham et al. (USA)$^{34}$ | Retrospective, T2DM | P, S | EMR (single center) | ORL, 54.6 | 93 | BMI: 48.3 | Weight: 152.0 | ORL, n = 29 | ORL + WL clinic, n = 18 |
| Hemo et al. (Israel)$^{35}$ | Retrospective | P, S | EMR (HMO) | 21–40 y, 42.4% | 41–60 y, 49.5% | > 60 y, 8.1% | 20.9 | BMI: 34.4 | ORL + SIB, n = 1340/n = 5501 | (Data are pooled) |
| Hendricks et al. (USA)$^{36}$ | Retrospective | S | Medical records (single center) | 49.6 | 15 | BMI: 35.6 | Weight: 98.8 | PHEN + WL program, n = 269 | WL program only, n = 31 |
| Hong et al. (UK)$^{37}$ | Retrospective | P | EMR (CPRD) | 47 | 22.6 | BMI: 36 | ORL, n = 33,625 |
| Author (country) | Study type/patient population | Healthcare setting | Data source | Baseline characteristics of study population<sup>b</sup> | Study drugs, n |
|-----------------|-------------------------------|--------------------|-------------|---------------------------------|---------------|
| Horie et al. (Brazil)<sup>38</sup> | Retrospective, ≥ 60 years | S | Medical records (single center) | | ORL, n = 11 SIB, n = 29 |
| Jick et al. (UK)<sup>39</sup> | Retrospective | | EMR (CPRD) | | PHEN, n = 862 |
| Lewis et al. (USA)<sup>40</sup> | Retrospective P | | EMR (PORTAL cohort) | | PHEN, n = 13,972 |
| Li et al. (USA)<sup>41</sup> | Retrospective S | | Medical records (single center) | | PHEN, n = 188 |
| Neoh et al. (Australia)<sup>42</sup> | Retrospective S | | EMR (single center) | | PHEN/TPM, n = 103 |
| Pardew et al. (Canada)<sup>43</sup> | Retrospective P, S | | Claims data (PharmaNet and British Colombia Linked Health) | | ORL, n = 16,968 SIB, n = 3466 |
| Perrio et al. (UK)<sup>44</sup> | Retrospective P | | Prescription records | | ORL, n = 16,021 SIB, n = 12,336 |
| Poongodi and Parthiban (India)<sup>45</sup> | Retrospective P, S | | AERS | | ORL |
| Ritchey et al. (USA)<sup>46</sup> | Retrospective P, S | | Claims data (Truven Health) | | PHEN/TPM, n = 14,586 PHEN/TPM (individual use), n = 19,184 PHEN, n = 124,334 |
| Shibuya et al. (USA)<sup>47</sup> | Retrospective P, S | | EMR (Cleveland Clinic) | | PHEN/TPM, n = 425 PHEN, n = 2372 NTX/BPN, n = 260 LORC, n = 354 |
| Wharton et al. (Canada)<sup>48</sup> | Retrospective S | | EMR (multicenter) | | LIR, n = 311 |

**RETROSPECTIVE STUDIES INCLUDING POSTSURGICAL PATIENTS**

| Author (country) | Study type/patient population | Healthcare setting | Data source | Baseline characteristics of study population<sup>b</sup> | Study drugs, n |
|-----------------|-------------------------------|--------------------|-------------|---------------------------------|---------------|
| Elhag et al. (Qatar)<sup>49</sup> | Retrospective Surgical and non-surgical | | EMR (single center) | | Non-surgical, 40.9 Surgical, 45.1 Non-surgical, 22.9 Surgical, 5.3 | Non-surgical, BMI: 38.3; Weight: 100.2 Surgical, BMI: 37.0; Weight: 94.8 |
| Author (country) | Study type/patient population | Healthcare setting<sup>a</sup> | Data source | Baseline characteristics of study population<sup>b</sup> |
|------------------|--------------------------------|-----------------------------|-------------|------------------------------------------------------|
| Nor Hanipah et al. (USA)<sup>50</sup> | Retrospective, surgical | S | Medical records (single center) | Age, years (mean or median) 50.9 Male, % 6.7 BMI kg/m<sup>2</sup> | PHEN, n = 25

| Rye et al. (Canada)<sup>51</sup> | Retrospective, surgical | S | Medical records (single center) | Age, years (mean or median) 49.6 Male, % 5 BMI ≥ 30 | LIRA, n = 20 |

| Schwartz et al. (USA)<sup>52</sup> | Retrospective, surgical | S | Medical records (single center) | Age, years (mean or median) PHEN, 46.8 PHEN/TPM, 48.9 Male, % 46.8 BMI kg/m<sup>2</sup> | PHEN, n = 52 |

| Toth et al. (USA)<sup>53</sup> | Retrospective, surgical (21–30 years) | S | Medical records (multicenter) | Age, years (mean or median) 21–25 y, 40.5% Male, % 8.1 BMI kg/m<sup>2</sup> | PHEN, n = 37<sup>f</sup> |

Abbreviations: AE, adverse event; AERS, adverse event reporting system; AOM, anti-obesity medication; BMI, body mass index; BPN, bupropion; CPRD, Clinical Practice Research Database; DM, diabetes mellitus; EMR, electronic medical records; HMO, Health Management Organization; LABG, laparoscopic-adjustable gastric band; LIRA, liraglutide; LORC, lorcaserin; M, male; NR, not reported; NTX, naltrexone; ORL, orlistat; P, primary care; PCMH, patient-centered medical home; PHEN, phentermine; PORTAL, Patient Outcomes Research to Advance Learning; PRO, patient-reported outcome; RYGB, Roux-en-Y gastric bypass; S, secondary care; SG, sleeve gastrectomy; SIB, sibutramine; T2DM, type 2 diabetes mellitus; TPM, topiramate; VA, Veteran’s Affairs; VLED, very-low energy diet; WL, weight loss.

<sup>a</sup>Secondary care also includes tertiary hospitals.

<sup>b</sup>Where a range of values are provided, this reflects multiple treatment groups.

<sup>c</sup>Where described, type of background measure varied across studies but included participation in weight-loss programs, education and counseling on lifestyle measures, dietary changes including very-low calorie diets, and increases in physical activity.

<sup>d</sup>n = number of SAE reports, not number of patients.

<sup>e</sup>Values are post-surgery, but pre-drug.

<sup>f</sup>Sample size for all patients who received AOMs after surgery; number of patients receiving phentermine specifically was not reported.
| Author (country) | Comparator | Background measures described, Y/Nc | Outcome(s) studied |
|------------------|------------|--------------------------------------|-------------------|
| **PROSPECTIVE STUDIES** | | | Weight | Cardiometabolic risk factors | Existing comorbidity | AEs | Economic | PRO | Adherence |
| Hayes et al. (UK)13 | SIB, n = 23,927 | N | ✓ | | | | | | ✓ |
| Hollywood and Ogden (UK)14 | Baseline (pre-drug) | Y | ✓ | | | | | | ✓ |
| Kim et al. (Korea)15 | Baseline (pre-drug) | N | ✓ ✓ | ✓ | | | | | |
| Rowe et al. (UK)16 | Baseline (pre-drug) | Y | ✓ ✓ ✓ ✓ | ✓ | | | | | |
| Schwartz et al. (USA)17 | Baseline (pre-drug) | Y | ✓ ✓ ✓ | ✓ | | | | | |
| Wirth (Germany)18 | Baseline (pre-drug) | Y | ✓ ✓ ✓ ✓ ✓ | ✓ | | | | | |
| **PROSPECTIVE STUDIES INCLUDING POSTSURGICAL PATIENTS** | | | | | | | | | |
| Suliman et al. (UAE)19 | Baseline (pre-drug) | N | ✓ ✓ | ✓ | | | | | |
| Wharton et al. (Canada)20 | Baseline (pre-drug) | Y | ✓ ✓ | ✓ | | | | | |
| **RETROSPECTIVE STUDIES** | | | | | | | | | |
| Aagaard et al. (Europe)21 | None | N | ✓ | | | | | | |
| Acharya et al. (UK)22 | None | N | ✓ ✓ | ✓ | | | | | |
| Ahn et al. (Korea)23 | Baseline (pre-drug) | Y | ✓ ✓ | ✓ | | | | | |
| Allie et al. (USA)24 | Baseline (pre-drug) | N | ✓ ✓ ✓ | ✓ | | | | | |
| Beermann et al. (Sweden)25 | Baseline (pre-drug) | Y | ✓ ✓ | ✓ | | | | | |
| Author (country) | Comparator | Background measures described, Y/N[^2] | Outcome(s) studied | Weight | Cardiometabolic risk factors | Existing comorbidity | AEs | Economic | PRO | Adherence |
|-----------------|------------|----------------------------------------|--------------------|--------|-----------------------------|----------------------|-----|----------|------|-----------|
| Costello et al. (USA)[^26] | Baseline (pre-drug) | Y | ✓ | | | ✓ | | | | |
| Czernichow et al. (The Netherlands)[^27] | Baseline (3 years pre-drug) | N | | ✓ | |
| Derby et al. (UK)[^28] | Matched obese, no AOM, n = 17,225 | N | | ✓ | |
| Douglas et al. (UK)[^29] | Non-use period (within patient comparison) | N | | ✓ | |
| Douglas et al. (UK)[^30] | Baseline (pre-drug) | Y | ✓ | ✓ ✓ ✓ ✓ ✓ | |
| Ganguly et al. (USA)[^31] | Matched obese non-exposed, n = 508,140 | N | ✓ | | |
| Gorgojo-Martinez et al. (Spain)[^32] | Baseline (pre-drug) | Y | ✓ ✓ ✓ ✓ ✓ ✓ | |
| Grabarczyk (USA)[^33] | Baseline (pre-drug) | Y | ✓ ✓ ✓ ✓ ✓ | |
| Graham et al. (USA)[^34] | Baseline (pre-drug) | Y | ✓ ✓ ✓ ✓ ✓ | |
| Hemo et al. (Israel)[^35] | Baseline (pre-drug) | N | ✓ ✓ ✓ ✓ ✓ | |
| Hendricks et al. (USA)[^36] | Baseline (pre-drug or pre-program) | Y | ✓ ✓ ✓ ✓ | |
| Hong et al. (UK)[^37] | Matched obese non-initiators, n = 160,347 | N | ✓ | | | | | | | |
| Author (country) | Comparator | Background measures described, Y/N<sup>c</sup> | Outcome(s) studied |
|-----------------|------------|---------------------------------------------|------------------|
|                 |            | Weight                                      | Cardiometabolic risk factors | Existing comorbidity | AEs | Economic | PRO | Adherence |
| Horie et al. (Brazil)<sup>38</sup> | Baseline (pre-drug) | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Jick et al. (UK)<sup>39</sup> | Matched obese non-initiators, n = 9281 | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Lewis et al. (USA)<sup>40</sup> | Baseline (pre-drug) Time-varying PHEN exposure categories | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Li et al. (USA)<sup>41</sup> | Baseline (pre-drug) | Y                                           | ✓                             | ✓               | ✓   |          |      |          |
| Neoh et al. (Australia)<sup>42</sup> | Pre-VLED/pre-drug End VLED/pre-drug | Y                                           | ✓                             | ✓               | ✓   |          |      |          |
| Padwal et al. (Canada)<sup>43</sup> | None | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Perrio et al. (UK)<sup>44</sup> | None | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Poongodi and Parthiban (India)<sup>45</sup> | None | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Ritchey et al. (USA)<sup>46</sup> | Periods of non-drug use in former users | N                                           | ✓                             | ✓               | ✓   |          |      |          |
| Shibuya et al. (USA)<sup>47</sup> | Baseline (pre-drug) Between drugs | Y                                           | ✓                             | ✓               | ✓   |          |      |          |
| Wharton et al. (Canada)<sup>48</sup> | Baseline (pre-drug) | Y                                           | ✓                             | ✓               | ✓   |          |      |          |

**RETRIEVEMENT STUDIES INCLUDING POSTSURGICAL PATIENTS**

| Author (country) | Comparator | Background measures described, Y/N<sup>c</sup> | Outcome(s) studied |
|-----------------|------------|---------------------------------------------|------------------|
| Elhag et al. (Qatar)<sup>49</sup> | Baseline (pre-drug) LORC (surgical and non-surgical) | Y                                           | ✓                             | ✓               | ✓   | ✓           |      |          |
| Author (country) | Comparator | Background measures described, Y/N<sup>c</sup> | Weight | Cardiometabolic risk factors | Existing comorbidity | AEs | Economic | PRO | Adherence |
|-----------------|------------|----------------------------------------------|--------|-----------------------------|----------------------|-----|----------|-----|----------|
| Nor Hanipah et al. (USA)<sup>50</sup> | Baseline (pre-drug) | Y | ✓ | | | | | | | |
| Rye et al. (Canada)<sup>51</sup> | Baseline (post-surgery, pre-drug) | Y | ✓ | | | | | | | |
| Schwartz et al. (USA)<sup>52</sup> | Baseline (pre-drug) Between drugs | Y | ✓ | ✓ | ✓ | ✓ | | | |
| Toth et al. (USA)<sup>53</sup> | Baseline (pre-drug) | N | ✓ | | | | | | | |

Abbreviations: AE, adverse event; AERS, adverse event reporting system; AOM, anti-obesity medication; BMI, body mass index; BPN, bupropion; CPRD, Clinical Practice Research Database; DM, diabetes mellitus; EMR, electronic medical records; HMO, Health Management Organization; LAGB, laparoscopic-adjustable gastric band; LIRA, liraglutide; LORC, lorcaserin; M, male; NR, not reported; NTX, naltrexone; ORL, orlistat; P, primary care; PCMH, patient-centered medical home; PHEN, phentermine; PORTAL, Patient Outcomes Research to Advance Learning; PRO, patient-reported outcome; RYGB, Roux-en-Y gastric bypass; S, secondary care; SG, sleeve gastrectomy; SIB, sibutramine; T2DM, type 2 diabetes mellitus; TPM, topiramate; VA, Veteran's Affairs; VLED, very-low energy diet; WL, weight loss.

<sup>a</sup>Secondary care also includes tertiary hospitals.

<sup>b</sup>Where a range of values are provided, this reflects multiple treatment groups.

<sup>c</sup>Where described, type of background measure varied across studies but included participation in weight-loss programs, education and counseling on lifestyle measures, dietary changes including very-low calorie diets, and increases in physical activity.

<sup>d</sup>n = number of SAE reports, not number of patients.

<sup>e</sup>Values are post-surgery, but pre-drug.

<sup>f</sup>Sample size for all patients who received AOMs after surgery; number of patients receiving phentermine specifically was not reported.
(n = 6), and NTX/BPN (n = 2). Weight change was the most studied outcome (n = 28), followed by AEs (n = 24), adherence/persistence/discontinuation (n = 21), and cardiometabolic risk factors (n = 13).

3.2 | Weight outcomes

Across the 28 studies including weight outcomes, regardless of study population, the most consistently reported measures were absolute weight reduction (in kg or lb; n = 22 studies), percentage reduction in body weight (n = 19), and categorical weight loss according to clinically meaningful thresholds (n = 15). The main findings from studies reporting on these measures are summarized in Table 3. Other weight outcomes included changes in BMI and waist-to-hip ratio, but these were seldom reported. Weight outcomes associated with orlistat (12 studies) or phentermine (10 studies) were the most reported; five studies reported on weight outcomes with PHEN/TPM and five with liraglutide, while only a single study included NTX/BPN (Table 3). Findings were pooled from multiple AOMs in two additional studies.\

3.2.1 | General obesity population

Across all studies in a general obesity population, AOMs were associated with a reduction in weight regardless of study design and duration. However, the magnitude of weight loss varied considerably from study to study (Table 3). With respect to achieving a clinically meaningful weight loss, the range of patients who lost ≥ 5% of their total body weight was 22.2% in a 12-week orlistat study,23 up to 50% in a 12-week phentermine study,26 and > 50% in two liraglutide studies (Table 3).32,48

Few studies were identified that directly compared different AOMs of interest. Findings from these comparative analyses are summarized in Table 4. Orlistat was associated with a significantly poorer weight-loss response compared with liraglutide after 3–6 months (p < 0.0001)32 and a numerically lower absolute weight reduction compared with phentermine and PHEN/TPM at ≥ 20 weeks in a general obesity population.33 Patients receiving phentermine or PHEN/TPM were more than 50% more likely to experience a ≥ 5% weight loss compared with those receiving orlistat (p < 0.01).33 In addition, in a matched cohort study, both phentermine and PHEN/TPM were associated with a greater weight reduction compared with NTX/BPN.47

3.2.2 | Diabetes population

Among the five studies that evaluated weight response among patients with obesity and T2DM, treatment with orlistat, phentermine, PHEN/TPM, and NTX/BPN was associated with a reduction in weight that appeared to be comparable with losses observed in a general population of individuals with obesity (Table 3).16,24,30,34,47 One study demonstrated that in patients with T2DM, orlistat in combination with participation in a clinical weight-loss program resulted in a numerically better weight-loss response compared with orlistat alone, although the difference failed to reach statistical significance (Table 3).34 In another study, no differences were reported in weight loss between patients with or without T2DM treated with phentermine, PHEN/TPM, or liraglutide, but a difference was demonstrated with NTX/BPN (T2DM, –4.8 kg vs. non-T2DM, –2.2 kg; p = 0.05; Table 3) although patient numbers were low (n = 32).47

3.2.3 | Postsurgical population

In patients with obesity who had previously undergone bariatric surgery and experienced subsequent weight regain or insufficient weight loss postoperatively, treatment with phentermine, PHEN/TPM, and liraglutide all resulted in weight reduction (Table 3).19,20,49–53 Weight loss was experienced across studies regardless of patient population (e.g., T2DM or young adults51,53) or surgery type. Furthermore, in one study, there was no apparent difference in percentage total weight loss with phentermine between surgical and non-surgical patients, and in another study, no difference was observed between surgical and non-surgical cohorts treated with liraglutide with respect to weight loss from baseline prior to drug initiation.19,49 Significantly greater weight reductions were, however, reported in a Canadian prospective cohort study among liraglutide-treated patients who had undergone RYGB compared with SG (Table 3).20 Similarly, in one study that pooled data from multiple AOMs, weight loss was greater in patients who received drug treatment following RYGB compared with those treated post-SG.50

Very few comparative data were available in surgical patients, but one study provided evidence that phentermine may produce superior weight loss compared with PHEN/TPM in surgical patients, although it should be noted that the number of patients receiving PHEN/TPM in this analysis was small (n = 6) (Table 4).52

3.3 | Cardiometabolic risk factors

Cardiometabolic risk factors were less well studied among the included articles. Thirteen studies overall (around 30% of those included; general obesity population [with or without DM], n = 12; surgical population, n = 1) evaluated the impact of AOMs on parameters including blood pressure, heart rate (HR), lipids, fasting blood glucose, and glycated hemoglobin (HbA1c). The effects of orlistat and phentermine were evaluated most frequently, followed by liraglutide and PHEN/TPM. Results varied across studies, with some demonstrating a positive impact on cardiometabolic risk factors and others showing no effect. An overview of the trends across studies is shown in Table 5.

3.3.1 | Orlistat

In the six studies that evaluated the effect of orlistat on blood pressure, systolic blood pressure (SBP) was significantly reduced in three studies and numerically reduced or unchanged in three, while no
| Study | Patient population | Baseline weight, kg | Weight change$^a$ | Categorical body weight loss |
|-------|--------------------|---------------------|------------------|-----------------------------|
|       |                    |                     | kg               | %                          |
| **ORLISTAT: PROSPECTIVE COHORTS** | | | | |
| Hollywood and Ogden$^{14}$ | General obesity | NR | $-4.09 \ (6.21)$ kg at 6 months | |
| Schwartz et al.$^{17}$ | 88.6 (19.5) kg | $-4.6 \ (0.7)$ kg at > 60 days | > 5%; > 60 day, 46.3% | |
| Wirth$^{18}$ | 99.2 kg | $-10.8 \ (6.9)$ kg at 6–9 months (all patients) | 5–10%; 6–9 months, 35.8% (all patients) | |
| Rowe et al.$^{16}$ | DM (91% T2DM) F, 98.1 (18.0) kg; M, 126.2 (23.7) kg | $-7.1$ kg at 6 months ($p < 0.001$ vs. baseline) | > 5%; 6 months, 51.2% | |
| **ORLISTAT: RETROSPECTIVE COHORTS** | | | | |
| Ahn et al.$^{23}$ | General obesity | 79.3 (14.1) kg | $-3.0 \ (2.0)$ kg at 12 weeks; $-3.6 \ (2.9)$ kg at 24 weeks ($p < 0.001$ vs. baseline both time points) | 5–10%; 12 weeks, 22.2%; 24 weeks, 34.9% | |
| Beerman et al.$^{25}$ | 99.3 (17.7) kg | 3 months: pre-drug diet weight loss < 2.5 kg, $-4.8 \ (3.4)$ kg; pre-drug diet weight loss ≥ 2.5 kg, $-5.4 \ (4.1)$ ($p = NS$ between groups) | 5 to < 10%; 38.4% (all patients), 40.2% (pre-drug diet loss < 2.5 kg), 36.5% (pre-drug diet loss ≥ 2.5 kg) at 3 months | |
| Douglas et al.$^{30}$ | NR | 1–4 months, $-0.94$ kg/month; 5–25 months, $+0.16$ kg/month; 26–36 months, $+0.01$ kg/month Small progressive weight increases in matched, non-exposed controls over 3 years | | |
| Gorgojo-Martinez et al.$^{32}$ | 107.8 (19.1) kg | $-3.8$ kg at 3–6 months; $-3.3$ kg at end of follow-up ($p < 0.0001$ vs. baseline both time points) | > 5%; 3–6 months, 30.7%; end of follow-up, 27.4% | |
| Grabarczyk$^{23}$ | 121.2 (26.2) kg | $-2.2 \ (12.8)$% at 12 weeks; $-2.1 \ (12.7)$% at ≥ 20 weeks; $-2.8 \ (14.5)$% at 36 weeks | ≥ 5%; 12 weeks, 23.5%; ≥ 20 weeks, 27.1% | |
**TABLE 3** (Continued)

| Study                  | Patient population | Baseline weight, kg | Weight changea | Categorical body weight loss |
|------------------------|--------------------|---------------------|----------------|-----------------------------|
|                        |                    |                     | Weight changea | %                           | Categorical body weight loss |
|                        |                    | 116 (24.6) kg       | –6.0 kg at 3–6 months ($p < 0.001$ vs. baseline) | –5% at 3–6 months |
| Allie et al.24         | T2DM               | 116 (24.6) kg       | 1–4 months, –0.78 kg/month; 5–25 months, +0.10 kg/month; 26–36 months, –0.03 kg/month |
| Douglas et al.30       | NR                 |                     | 6.0 kg at 3–6 months ($p < 0.001$ vs. baseline) | 5% at 3–6 months |
| Graham et al.34        | ORL + WL clinic, 134.5 (23.6) kg; ORL alone, 152 (28) kg | 6 months: ORL + WL clinic, –5.0 (6.0) kg ($p = 0.005$ vs. baseline); ORL alone, –2.2 (4.7) kg ($p = 0.027$ vs. baseline) ($p =$ NS between groups) | ≥ 5%: 28% (ORL + WL clinic), 14% (ORL alone) at 6 months ($p =$ NS between groups) |
| Douglas et al.30       | CVDb               | NR                  | 1–4 months, –0.97 kg/month; 5–25 months, +0.13 kg/month; 26–36 months, 0.00 kg/month |
| Horie et al.38         | ≥ 60 years         | 96.2 (15.78) kg     | –3.30 (5.86) kg at 9 months |

**PHENTERMINE: PROSPECTIVE COHORTS**

| Study                  | Patient population | Baseline weight, kg | Weight changea | %                           | Categorical body weight loss |
|------------------------|--------------------|---------------------|----------------|-----------------------------|-----------------------------|
| Kim et al.15           | General obesity    | Men, 94.2 (18.3) kg; Women, 67.8 (11.6) kg | –3.8 (4.0) kg at 12 weeks | –5.2% at 12 weeks | ≥ 5%: 12 weeks, 45.6% |

**PHENTERMINE: RETROSPECTIVE COHORTS**

| Study                  | Patient population | Baseline weight, kg | Weight changea | %                           | Categorical body weight loss |
|------------------------|--------------------|---------------------|----------------|-----------------------------|-----------------------------|
| Grabarczyk23           | General obesity    | 121.5 (29) kg       | –2.1 (14.2)% at 12 weeks; –3.6 (11.9)% at ≥ 20 weeks; –2.5 (14.4)% at 36 weeks | ≥ 5%: 12 weeks, 30.5%; ≥ 20 weeks, 38.5% |
| Hendricks et al.36     | PHEN + WL program, 98.4 (24.5) kg; WL program, 102.7 (19.8) kg | 12 weeks: PHEN + WL program, –15.1 (4.0)% vs. WL program, –12.8 (3.9)% 26 weeks: –18.9 (6.5)% vs. –17.4 (6.0)% 52 weeks: –17.6 (7.8)% vs. –16.1 (9.7)% 104 weeks: –12.7 (8.2)% vs. –8.4 (10.7)% ($p = 0.0144$ between groups) | ≥ 5%: 97% (PHEN), 80% (WL program only) at 52 weeks |
| Study                  | Patient population                                    | Baseline weight, kg | Weight change\(^a\) | Categorical body weight loss |
|-----------------------|------------------------------------------------------|---------------------|----------------------|-----------------------------|
|                       |                                                      |                     | kg                   | %                           |                               |
| Lewis et al.\(^{40}\) | NR                                                   |                     |                      | 6 months: short-term use, –2.7%; medium-term use, –7.7\(^c\) |
|                       |                                                      |                     |                      | 12 months: –1.4%; –6.0%     |
|                       |                                                      |                     |                      | 24 months: –0.2%; –1.9%; long-term use, –7.5\(^c\) |
| Li et al.\(^{41}\)    | Men, 124.9 (SEM, 28.2) kg; Women, 103.4 (24.0) kg     | –7.6 (4.4) kg (men), –6.3 (3.4) kg (women) at 8 weeks |                      | ≤5%: 12 weeks, 39%          |
|                       |                                                      | –9.7 (5.3) kg (men), –8.0 (6.5) kg (women) at 12 weeks |                      |                               |
| Shibuya et al.\(^{42}\)| 104.7 (24.8) kg                                      | –3.8 (5.9) kg at 12 weeks (\(p < 0.0001\) vs. baseline) | –3.75% at 12 weeks |                               |
| Elhag et al.\(^{43}\) | Surgical, 94.8 (18.2) kg; Non-surgical, 100.2 (20.9) kg | 3 months: surgical, –7.6 (10.32) kg (–7.62%); non-surgical, –8.42 (9.69) kg (–7.65%) | 3 months: surgical, –7.62%; non-surgical, –7.65% | 5–9.9%: 21.1% (surgical), 20.8% (non-surgical) at 3 months |
| Schwartz et al.\(^{52}\) | Surgical; 21–30 years NR                              | 3 months: T2DM, –3.30 (7.49) kg; non-T2DM, –3.99 (5.67) kg (\(p = 0.21\) vs. T2DM) | Median –7.7% at nadir weight |                               |
| Shibuya et al.\(^{47}\) | T2DM\(^{49}\)                                         | 111.1 (25.4) kg     | –6.3 kg at 90 days   | –12.8% at 90 days            |
| PHENTERMINE/TOPIRAMATE: RETROSPECTIVE COHORTS |                                                   |                     |                      |                               |
| Costello et al.\(^{26}\) | General obesity, Median (range), 115.5 (75.8 to 134.5) kg | –2.2 kg (–16.8 to 0.1) kg at 12 weeks | –2.8% at 12 weeks |                               |
| Grabarczyk\(^{33}\)   | 124.7 (29.5) kg                                      | –7.4 kg at nadir weight (\(p = 0.01\) vs. post-VLED, pre-drug) | –3.4 (14.2)% at 12 weeks; –4.1 (12.6)% at ≥ 20 weeks; –4.3 (14.1)% at 36 weeks | ≥5%: 12 weeks, 34.1%; ≥ 20 weeks, 40.3% |
| Neoh et al.\(^{42}\)  | 122.5 (29.7) kg (post-VLED, pre-drug)               | –4.8 kg at final weight (\(p = 0.01\) vs. post-VLED, pre-drug) | –7.4 kg at nadir weight (\(p = 0.01\) vs. post-VLED, pre-drug) |                               |
| Shibuya et al.\(^{47}\) | 104.1 (22.8) kg                                      | –3.76 (5.6) kg at 12 weeks (\(p < 0.0001\) vs. baseline) | –3.63% at 12 weeks |                               |
| Schwartz et al.\(^{52}\) | Surgical, 105.8 (22.8) kg                            | –3.8 kg (–12.9%) at 90 days | –12.9% at 90 days |                               |
| Shibuya et al.\(^{47}\) | T2DM\(^{49}\)                                         | 3 months: T2DM, –3.40 (5.72) kg; non-T2DM, –3.88 (5.23) kg (\(p = 0.72\) vs. T2DM) | –7.7% at nadir weight |                               |
| Study                     | Patient population  | Baseline weight, kg | Weight change * | Categorical body weight loss |
|--------------------------|---------------------|---------------------|-----------------|----------------------------|
| **LIRAGLUTIDE: PROSPECTIVE COHORTS** |                      |                     |                 |                            |
| Suliman et al. 19        | General obesity     | 97.9 kg             | –6.0 kg (95% CI 2.4, 9.4) at ≥ 16 weeks; –7.4 kg (–3.5, –11.0) at ≥ 28 weeks | –6.4% at ≥ 16 weeks; –7.6% at ≥ 28 weeks |
| Suliman et al. 19        | Surgical            | NR                  | ≥ 16 weeks: surgical, –6.4%; non-surgical, –6.1% (p < 0.0001 vs. baseline both groups) | RYGB vs. SG at ≥ 28 weeks, –5.6% vs. –3.3% (p = 0.025) |
| Wharton et al. 20        | NR                  | 7.6 months (mean follow-up); all patients, –6.3 (7.7) kg; RYGB, –7.1 (8.7) kg; gastric band, –6.0 (7.2) kg; SG, –4.5 (4.5) kg (p < 0.05 vs. baseline, all groups) | 7.6 months (mean follow-up); all patients, –5.5%; RYGB, –6.6%; gastric band, –4.9%; SG, –3.6% |
| **LIRAGLUTIDE: RETROSPECTIVE COHORTS** |                      |                     |                 |                            |
| Gorgojo-Martínez et al. 32 | General obesity     | 105.1 (18.6) kg     | –6.4 kg (95% CI –7.5, –5.3) at 3–6 months; –7.7 kg (–9.0, –6.3) at end of follow-up (p < 0.0001 vs. baseline, both time points) | > 5%; ≥ 3–6 months, 56.5%; end of follow-up, 64.7% |
| Wharton et al. 48        | All, 115.5 (28.4) kg; ≥ 6 months persistent, 117.6 (31) kg; ≥ 4 months persistent, 115.9 (28.8) kg | 6 months: all patients, –7.3 kg; ≥ 6 months persistent, –8.0 kg; ≥ 4 months persistent, –7.0 kg (p < 0.001 vs. baseline, all groups) | 6 months: all patients, –6.5%; ≥ 6 months persistent, –7.1%; ≥ 4 months persistent, –6.3% |
|                          | NR                  |                     |                 |                           |
|                          | Rye et al. 51       | Surgical            | NR              | Median –7.1% (IQR, –5.1 to –12.2%) at 16 weeks; –9.7% (–7.8 to –13.9%) at 28 weeks |
|                          | Surgical, T2DM (n = 5) | NR              |                 | Median –5.7% (IQR, –4.9 to –8.5%) at 16 weeks; –8.4% (–7.7 to –9.1%) at 28 weeks |
| **NALTREXONE/BUPROPION: RETROSPECTIVE COHORTS** |                      |                     |                 |                            |
| Shibuya et al. 47        | General obesity     | 110.5 (26.6) kg     | –2.9 (5.5) kg (–2.66%) at 12 weeks (p < 0.0001 vs. baseline) | –2.66% at 12 weeks ≥ 5%; 12 weeks, 29.2% |
| Shibuya et al. 47        | T2DM                | NR                  | 3 months: T2DM, –4.79 (4.92) kg; non-T2DM, –2.16 (4.76) kg (p = 0.05 vs. T2DM) | |

(Continues)
effect or a numerical decrease in diastolic blood pressure (DBP) was observed in four studies and a significant reduction reported in two (Table 5). Triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) were generally reduced in association with orlistat treatment, while impact on high-density lipoprotein cholesterol (HDL-C) was more variable (Table 5). Glycemic parameters were consistently reduced in patients with obesity and DM (mostly T2DM) who received orlistat.16,18,24,32,34 One German postmarketing study also evaluated the effects of orlistat on cardiometabolic risk factors in subgroups of patients with comorbidities and demonstrated that improvements in blood pressure or lipid parameters were greater in individuals with hypertension or dyslipidemia, respectively.18

In a single comparative study, no clinically significant differences from baseline to 6 months in blood pressure, lipids, or HbA1c was observed between patients treated with orlistat, phentermine, or PHEN/TPM.33

### 3.3.2 | Phentermine and PHEN/TPM

Like orlistat, phentermine appeared to be associated with a reduction in SBP (Table 5). However, small increases in HR from baseline were reported in phentermine-treated patients, although this did not reach statistical significance.36,40 Two studies reported on the effect of PHEN/TPM on cardiometabolic risk factors, with few changes in blood pressure, lipids, or glycemia observed (Table 5).33,42

### 3.3.3 | Liraglutide

Few data (n = 2 studies) were identified regarding the impact of liraglutide on cardiometabolic risk factors (Table 5). Where studied, liraglutide was generally associated with a reduction in blood pressure, lipids, and glycemic parameters.32,48

### 3.3.4 | Postsurgical patients

No changes in lipid or glycemic parameters were reported in a single study including patients who received phentermine for weight gain/insufficient weight loss after bariatric surgery (Table 5).49

### 3.4 | Existing comorbidities

Five of the identified studies in a general obesity population (with or without T2DM) also evaluated the impact of AOMs on existing comorbidities, which was generally reported as a change in specific medications. For example, antihypertensive, glucose-lowering, and lipid-lowering drug use was reported to be reduced following orlistat initiation in three studies including patients with obesity and comorbid diseases,16,18,27 but another study in patients with T2DM...
failed to demonstrate any significant changes. Resolution of baseline prediabetes occurred in fewer orlistat-treated patients with obesity compared with liraglutide-treated patients in a Spanish observational study and more patients progressed to T2DM (6.1% vs. 0%; \( p < 0.0001 \)) at last study visit \( 7.06 (3.81, 13.07) \) \( p < 0.0001 \) both time points.

### 3.4.1 Postsurgical patients

Both phentermine and PHEN/TPM failed to have an impact on comorbid hypertension and DM in post-bariatric surgery patients.

### 3.5 Adverse events

Data on the incidence of AEs in AOM-treated patients were reported in 24 studies overall (57% of included) and the level of detail in the data varied considerably between investigations. Of these studies, 22 were in general obesity populations (with or without DM), two pooled AE data across surgical and nonsurgical patient cohorts, and two specifically reported AE data in postsurgical patients. Overall, AE data were reported most frequently for orlistat \( (n = 12 \) studies) and phentermine \( (n = 9 \) ), with only four and two studies providing information regarding liraglutide or PHEN/TPM, respectively. No AE data were

---

### TABLE 4 Weight outcomes (body weight change and categorical body weight loss) in active comparator studies

| Study | Study population Drugs compared | Weight loss, kg and/or % | Categorical weight loss |
|-------|---------------------------------|--------------------------|-------------------------|
| Gorgojo-Martínez, et al.32 | General obesity LIRA vs. ORL | Crude mean difference: \(-2.53 \text{ kg (95\% CI } -3.67, -1.4) \) at 3-6 months \( (p < 0.001) \) | OR (95\% CI) for \( \geq 5\% \) loss, LIRA vs. ORL: 3-6 months, 3.32 (1.90, 6.04); last study visit, 7.06 (3.81, 13.07) \( p < 0.0001 \) both time points |
| Grabarczyk33 | General obesity ORL, PHEN, PHEN/TPM, LORC | At \( \geq 20 \) weeks: ORL, \(-2.1\% \); PHEN, \(-3.6\% \); PHEN/TPM, \(-4.1\% \); LORC, \(-3.6\% \) \( (p = \text{NS between groups}) \) | \( \geq 5\% \) loss at \( \geq 20 \) weeks: ORL, 27.1%; PHEN, 38.5%; PHEN/TPM, 40.3%; LORC, 34.6% \( (p = \text{NS between groups}) \) |
| Li et al.41 | General obesity PHEN vs. PHEN/FEN | NS difference in men and women at 8 and 12 weeks Women at 4 weeks: PHEN, \(-3.6 \text{ kg vs. PHEN/FEN, } -4.1 \text{ kg (} p = 0.042) \) | 5-9.99% loss at 3 months, PHEN vs. LORC: non-surgical, 20.8% vs. 8.6%; surgical, 21.1% vs. 25.9% |
| Shibuya et al.47 | General obesity PHEN, PHEN/TPM, LORC, NTX/BPN | Weight loss difference at 12 weeks (PSM cohorts): PHEN vs. PHEN/TPM, 0.14 (8.51) kg \( (p = \text{NS}) \); PHEN vs. LORC, 1.46 (10.95) kg \( (p = 0.013) \); PHEN vs. NTX/BPN, 1.14 (8.36) kg \( (p = 0.030) \) PHEN/TPM vs. LORC, 1.48 (11.47) kg \( (p = 0.026) \); PHEN/TPM vs. NTX/BPN, 0.77 (7.51) kg \( (p = \text{NS}) \) LORC vs. NTX/BPN, 0.64 (11.96) kg \( (p = \text{NS}) \) | 5-9.99% loss at 3 months, PHEN vs. LORC: non-surgical, 20.8% vs. 8.6%; surgical, 21.1% vs. 25.9% |
| Elhag et al.49 | Surgical and non-surgical PHEN vs. LORC | Non-surgical at 3 months PHEN, \(-8.42 \text{ (9.69) kg (} -7.65 \text{ (8.26)%}; \ p = 0.003 \) vs. LORC LORC, \(-2.98 \text{ (4.15) kg (} -2.99 \text{ (3.72)%}; \ p = 0.032) \) Surgical at 3 months PHEN, \(-7.68 \text{ (10.32) kg (} -7.62 \text{ (9.80)%); \ p = 0.012 \) vs. LORC LORC, \(-1.81 \text{ (4.54) kg (} -1.86 \text{ (5.06)%);} \) | 5-9.99% loss at 3 months, PHEN vs. LORC: non-surgical, 20.8% vs. 8.6%; surgical, 21.1% vs. 25.9% |
| Schwartz et al.52 | Surgical PHEN vs. PHEN/TPM | Weight difference at 90 days: \(-1.35 \text{ kg (95\% CI 0.17, 2.53); } p = 0.025 \) | 5-9.99% loss at 3 months, PHEN vs. LORC: non-surgical, 20.8% vs. 8.6%; surgical, 21.1% vs. 25.9% |

Note: Only studies that included a comparison with a drug of interest are listed here. Abbreviations: AOM, anti-obesity medication; BPN, bupropion; CI, confidence interval; FEN, fenfluramine; LIRA, liraglutide; LORC, lorcaserin; NS, not statistically significant; NTX, naltrexone; OR, odds ratio; ORL, orlistat; PHEN, phentermine; PSM, propensity score matched; TPM, topiramate.
identified for NTX/BPN. Where reported, AEs appeared to be mild to moderate in severity and were mostly short-lived.

### 3.5.1 | Orlistat

In orlistat studies, AEs affecting the gastrointestinal system were the most commonly reported events.\(^17,18,21–23,32,34,44,45\) Acute liver injury and colorectal cancer were specifically evaluated in orlistat-treated patients included in the UK Clinical Practice Research Database (CPRD) and no increase in the incidence of either event was observed.\(^29,37\)

### 3.5.2 | Phentermine and PHEN/TPM

A range of different AEs was reported in phentermine-treated patients, with palpitations, dry mouth, insomnia, constipation, fatigue, and dizziness being among the most common.\(^15,36,41,49\) Cardiovascular (CV) and cerebrovascular events were specifically evaluated in four studies. In two nested case–control studies that used data from the UK CPRD, no increase in the incidence of stroke or cardiac-valve abnormalities was observed in patients treated with phentermine.\(^28,39\) In a US retrospective cohort study that used data from electronic medical records, it was demonstrated that there was no increase in the risk of CV disease or death with phentermine use for up to 3 years after initiation.\(^40\)

### Table 5

| Study | Study population | Study duration, months | SBP | DBP | HR | TG | TC | LDL-C | HDL-C | FBG | HbA1c |
|-------|-------------------|-----------------------|-----|-----|----|----|----|-------|-------|-----|-------|
| ORLISTAT | Ahn et al.\(^23\) | General obesity | 6 |  |  |  |  |  |  |  |  |
| | Gorgojo-Martínez et al.\(^32\) | 3–6 |  |  |  |  |  |  |  |  |  |
| | Grabarczyk\(^23\) | 6 |  |  |  |  |  |  |  |  |  |
| | Wirth\(^18\) | 6–9 |  |  |  |  |  |  |  |  |  |
| | Allie et al.\(^24\) | DM\(^b\) | 3–6 |  |  |  |  |  |  |  |  |
| | Gorgojo-Martínez et al.\(^32\) | 3–6 |  |  |  |  |  |  |  |  |  |
| | Graham et al.\(^34\) | 6 |  |  |  |  |  |  |  |  |  |
| | Rowe et al.\(^16\) | 6 |  |  |  |  |  |  |  |  |  |
| | Wirth\(^18\) | 6–9 |  |  |  |  |  |  |  |  |  |
| | Wirth\(^18\) | Dyslipidemia | 6–9 |  |  |  |  |  |  |  |  |
| | Wirth\(^18\) | Hypertension | 6–9 |  |  |  |  |  |  |  |  |
| PHENTERMINE | Grabarczyk\(^33\) | General obesity | 6 |  |  |  |  |  |  |  |  |
| | Hendricks et al.\(^26\) | 12–24 |  |  |  |  |  |  |  |  |  |
| | Kim et al.\(^15\) | 3 |  |  |  |  |  |  |  |  |  |
| | Lewis et al.\(^40\) | 12–24 |  |  |  |  |  |  |  |  |  |
| | Elhag et al.\(^49\) | Surgical | 3 |  |  |  |  |  |  |  |  |
| PHENTERMINE/TOPIRAMATE | Grabarczyk\(^33\) | General obesity | 6 |  |  |  |  |  |  |  |  |
| | Neoh et al.\(^42\) | To nadir weight |  |  |  |  |  |  |  |  |  |
| LIRAGLUTIDE | Gorgojo-Martínez et al.\(^32\) | General obesity | 3–6 |  |  |  |  |  |  |  |  |
| | Wharton et al.\(^48\) | 6 |  |  |  |  |  |  |  |  |  |

Abbreviations: DBP, diastolic blood pressure; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.

Note: ↑ and ↓ indicates increase or decrease vs. baseline (pre-drug) levels; ↔ indicates no change vs. baseline (pre-drug) values.

\(^a\)Subanalysis including the 20.3% of patients with obesity and T2DM.

\(^b\)Specifically T2DM in Allie et al.\(^24\), Gorgojo-Martínez et al.\(^32\) and Graham et al.\(^34\); 91% T2DM in Rowe et al.\(^16\); DM type not specified in Wirth.\(^18\)

\(^c\)HDL-C reduction in ORL-only group, not ORL + WL clinic; significant HbA1c reduction only in ORL + WL clinic (p = NS ORL alone).

\(^d\)Significant reduction from baseline in parameters in patients with and without DM, dyslipidemia, and hypertension, but reduction was greater in subgroups with comorbidities.

\(^e\)Phentermine-treated patients also enrolled in a highly prescriptive weight-management program; increase in HR phentermine-treated patients only versus decrease in WL program only group.

\(^f\)Data from medium and long-term continuous users of phentermine.

*Statistically significant within-arm increase or decrease vs. baseline (pre-drug) values.
US study that utilized claims data also found that there was no increase in the risk of major adverse CV events (MACE; hospitalization for acute myocardial infarction [MI], stroke, or in-hospital CV death) in phentermine users. Similarly, this study also demonstrated no increase in the risk of MACE in current users of PHEN/TPM. In one other study that provided data for PHEN/TPM-treated patients, it was reported that paresthesia, cognitive changes, dry mouth, and headache were the most common AEs.

3.5.3 | Liraglutide

AEs associated with liraglutide were reported in two studies in a general obesity population. The most common AEs in liraglutide-treated patients were mostly gastrointestinal in nature, including nausea and vomiting, and diarrhea.

3.5.4 | Postsurgical patients

Two studies evaluated AEs associated with liraglutide in patients who had previously undergone bariatric surgery. Among the most commonly reported AEs were nausea, headache, constipation, and diarrhea.

3.6 | Adherence, persistence, and discontinuation

Compliance outcomes comprising adherence, persistence, and discontinuation were reported in 21 studies (50% of included records): general obesity population (n = 18), pooled surgical and nonsurgical cohorts (n = 1), and postsurgical (n = 2). Overall, orlistat was the most frequently evaluated AOM in this regard (n = 14 studies), followed by liraglutide (n = 5), phentermine (n = 4), PHEN/TPM (n = 3), and NTX/BPN (n = 1). The main findings with respect to these outcomes are summarized in Table 6. Across studies, adherence, persistence, and discontinuation were measured in multiple different ways, rendering it impossible to compare outcomes from one investigation to the other. However, there was a general pattern of poor compliance with all AOMs. For example, in a US retrospective observational cohort study using data from the Veterans Affairs Corporate Data Warehouse that used the medication possession ratio (MPR) to determine 6-month adherence, the highest rate reported was only 38.2% in PHEN/TPM-treated patients, with other AOMs performing even more poorly (Table 6). Low adherence was similarly reported in another US study that used proportion of days covered as the metric. This study also provided estimates of persistence and demonstrated that only 18.1%, 27.3%, and 41.8% of patients treated with NTX/BPN, PHEN/TPM, or liraglutide, respectively, were persistent at 6 months. High proportions of patients discontinued treatment within 6–12 months (Table 6); reported reasons included AEs and perceived lack of weight-loss effectiveness.

3.6.1 | Comparative studies

A direct comparison between different AOMs was undertaken in four retrospective studies (Table 6). In one study, more patients remained on liraglutide at 12 months versus orlistat (p = 0.011) and at the end of follow-up persistence was higher (55% vs. 19.5%; p < 0.0001). However, after adjustment for baseline factors, there was no significant difference between the persistence curves. A significantly lower risk of discontinuation with liraglutide was demonstrated in another study compared with PHEN/TPM and NTX/BPN after adjustment for baseline factors. Conversely, where studied, adherence and persistence were generally worse with orlistat compared with liraglutide (unadjusted analysis), PHEN/TPM, and phentermine.

3.6.2 | Postsurgical patients

Limited data were identified regarding compliance outcomes in postsurgical patients. In one study, discontinuation was observed in 24% of patients treated with liraglutide within 1 year, with the most common reasons being lack of weight loss efficacy, cost, and AEs.

4 | DISCUSSION

The current review identified numerous studies that provide evidence for the effectiveness and tolerability of AOMs in real-world practice and describe an experience more typical of patients who are seeking weight-loss solutions from their healthcare professional. Although there was a wide disparity in designs, patient populations, and durations across studies that challenged the drawing of definitive conclusions, it was clear that available AOMs were associated with a reduction in weight from baseline in a general obesity population, and these data do appear to support the efficacy of AOMs previously reported in tightly controlled RCTs. Limited evidence from the included studies also suggests that in a general obesity population, AOMs may be accompanied by positive changes in other cardiometabolic risk factors that could be indicative of downstream improvements in existing obesity-related comorbidities such as T2DM, dyslipidemia, and hypertension. However, few studies evaluated these outcomes and those that did generally used a reduction in drug use for specific conditions as a surrogate and were of insufficient duration to robustly capture significant improvements. Furthermore, comorbidities beyond the usual cardiometabolic risk factors of blood pressure, lipids, and glycemic parameters were not assessed. Other comorbidities known to have strong associations with obesity, such as non-alcoholic steatohepatitis, obstructive sleep apnea, arthritis, depression, and cancer, were not represented.

Some of the data from patient subpopulations warrants further discussion. In contrast to RCTs, which have consistently shown less weight loss with AOMs in populations with T2DM compared to those without T2DM, the few real-world studies that evaluated these drugs
| Study                        | Study population | Adherence                                      | Persistence                                      | Discontinuations | AOM comparisons |
|-----------------------------|------------------|------------------------------------------------|-------------------------------------------------|------------------|-----------------|
| ORLISTAT: PROSPECTIVE       | Hollywood and Ogden\(^a\) | General obesity | Self-rated total adherence, 30.4% | Adherence: ORL < PHEN/TPM | 47.5% discontinued by 6 months |
| Schwartz et al.\(^b\)       |                  |                                                     | ORL used for median 90% of days since study enrollment |                  | 8.5% discontinued due to AEs |
| Wirth\(^b\)                 |                  | Physician-rated compliance: excellent, 21.3%; good/very good, 61.8%; moderate, 10.7%; inadequate, 5.1%; missing, 1.1% | Mean duration use, 7.1 months |                  |                  |
| ORLISTAT: RETROSPECTIVE     | Acharya et al.\(^c\); Perrio et al.\(^d\) | General obesity | Complete adherence to approved indication, 6.5% |                  | 30.3% discontinued in first 3 months; 68.9% by study end |
| Beermann et al.\(^e\)       |                  |                                                     | Persistence: 3–6 months, 64.8%; 12 months, 46.8%; end of follow-up, 19.5% |                  | Persistence: ORL < LIRA |
| Gorgojo-Martínez et al.\(^f\)|                  |                                                     | Persisted interrupted therapy at least once for ≥7 days and restarted within follow-up period, 35.8% |                  |                  |
| Grabarczyk\(^g\)            |                  | 6-month MPR ≥ 80%, 17.5%; MPR, 0.50 (0.26)         | Adherence: ORL < PHEN/TPM                        |                  |                  |
| Hemo et al.\(^h\)           |                  |                                                     | Persistence: ≥4 months, 15.5% Average duration of therapy, 21 months |                  | Persistence: SIB > ORL (p < 0.001) |
| Padwal et al.\(^i\)         |                  |                                                     | Persistence: 6 months, 18%; 1 year, 6%; 2 years, 2% |                  |                  |
| Allie et al\(^j\)           | T2DM             |                                                     | 44% discontinued within 3 months of initiation |                  |                  |
| Graham et al.\(^k\)         |                  | ORL vs. ORL + WL program: no difference in adherence (p = 0.865)\(^l\) | Discontinued within 6 months: 34% (all patients); 17% (ORL); 61% (ORL + WL program) (p = 0.004 vs. ORL alone) |                  |                  |
| Rowe et al.\(^m\)           | DM (91% T2DM)    |                                                     | 18% discontinued within 6 months |                  |                  |
| Horie et al.\(^n\)          | ≥ 60 years       |                                                     | Mean (SD) duration of therapy, 8.7 (5.0) months |                  |                  |
| Study | Study population | Adherence | Persistence | Discontinuations | AOM comparisons |
|-------|------------------|-----------|-------------|------------------|-----------------|
| **PHENTERMINE: PROSPECTIVE** | | | | | |
| Kim et al.15 | General obesity | Good compliance in 26.3%<sup>6</sup> | 62% completed 12-week treatment | 9.0% discontinued within 12 weeks due to AEs | |
| **PHENTERMINE: RETROSPECTIVE** | | | | | |
| Grabarczyk<sup>23</sup> | General obesity | 6-month MPR ≥ 80%, 29.4%; MPR, 0.57 (0.29) | | | 8.3% of male patients discontinued by week 8 3.9% of female patients discontinued by week 4; 7.8% by week 8 No further discontinuations by week 12 |
| Li et al.<sup>41</sup> | | | | | |
| Schwartz et al.<sup>52</sup> | Surgical | | | | No discontinuations due to hypertension, cardiac arrhythmias, or insomnia; one discontinuation each due to headaches and nausea |
| **PHENTERMINE/TOPIRAMATE: RETROSPECTIVE** | | | | | |
| Grabarczyk<sup>23</sup> | General obesity | 6-month MPR ≥ 80%, 38.2%; MPR, 0.65 (0.26) | | | Adherence: PHEN/TPM > ORL (p < 0.05) |
| Ganguly et al.<sup>31</sup> | 6-month PDC ≥ 80%, 20.6%; PDC, 0.47 (0.29) | Persistence: 3 months, 49.0%; 6 months, 27.3%; 9 months, 16.8%; 12 months, 10.9%; ≥ 1 prescription refill beyond index claim, 72% Switch to alternative AOM, 13.7% (to LORC, 27.3%; to LIRA, 28.0%; to NTX/BPN, 44.8%) | | Persistence: PHEN/TPM < LIRA Discontinuation: PHEN/TPM > LIRA |
| Schwartz et al.<sup>52</sup> | Surgical | | | | No discontinuations due to hypertension, cardiac arrhythmias, or insomnia |
| **LIRAGLUTIDE: PROSPECTIVE** | | | | | |
| Suliman et al.<sup>19</sup> | General obesity | | | 20% discontinued after median 108 days; 6.7% of study population due to AEs | |
| Wharton et al.<sup>20</sup> | Surgical | Persistence: 36.8% at 1 year | | 23.9% discontinued by 1 year | (Continues) |
| Study Population | Adherence | Persistence | Discontinuations | AOM Comparisons |
|------------------|-----------|-------------|------------------|-----------------|
| **LIRAGLUTIDE: RETROSPECTIVE** |
| Ganguly et al.31  | General obesity 6-month PDC ≥ 0.80, 27.4%; PDC, 0.56 (0.28) | Persistence: 3 months, 62.6%; 6 months, 41.8%; 9 months, 33.0%; 12 months, 28.2% Switching in first 6 months, 3.7%; to LORC, 21.7%; to NTX/BPN, 54.6%; to PHEN/TPM, 23.7% | Discontinuations: LIRA > LORC (HR, 0.46), NTX/BPN (HR, 0.48), PHEN/TPM (HR, 0.64) (p < 0.0001) |  |
| Gorgojo-Martínez et al.32 | Persistence: 3–6 months, 75%; 12 months, 61%; end of follow-up, 55% Therapy interruption at least once for ≥ 7 days, with restart within follow-up, 11% | Persistence: LIRA > ORL at 3–6 months (p = 0.052), 12 months (p = 0.011), and end of follow-up (p < 0.0001) Therapy interruption: LIRA < ORL (p < 0.0001) |  |
| Wharton et al.48 | Persistence: ≥ 4 months, 67.5%; ≥ 6 months, 53.7% | Discontinuations: ≥ 4-month persistent cohort, 28.1%; ≥ 6-month persistent cohort, 51.5% |  |
| **NALTREXONE/BUPROPION: RETROSPECTIVE** |
| Ganguly et al.31  | General obesity 6-month PDC ≥ 80%, 11.1%; PDC, 0.38 (0.26) | Persistence: 3 months, 34.2%; 6 months, 18.1%; 9 months, 12.7%; 12 months, 9.2% Switching to alternative AOM, 6.9%; to LIRA, 40.7%; LORC, 35.1%; PHEN/TPM, 24.2% | Persistence: NTX/BPN < LIRA Discontinuation: NTX/BPN > LIRA |  |

Abbreviations: AE, adverse event; AOM, anti-obesity medication; BMI, body mass index; BPN, bupropion; DM, diabetes mellitus; LIRA, liraglutide; LORC, lorcaserin; MPR, medication possession ratio; NTX, naltrexone; ORL, orlistat; PDC, proportion of days covered; PHEN, phentermine; SD, standard deviation; SIB, sibutramine; T2DM, type 2 diabetes mellitus; TPM, topiramate; WL, weight loss.

*aRated on a 5-point scale; unclear from the publication whether compliance just relates to medication adherence or to all aspects of management, including dietary restrictions.

*bComplete adherence to approved indication characterized as having correct BMI at initiation, approved weight reduction during the pre-drug diet period, and continued orlistat treatment after 3 months only with an approved weight reduction of ≥ 5%.

*cAdherence for the ORL + WL program group was defined as patients taking 120–360 mg/d, as the number of pills per day may vary with number of meals consumed. Thus, if ≥ 1 dose was ingested daily, the patient was considered adherent. Adherence for ORL-only patients was defined as taking ≥ 80% of their weekly dose or having computerized prescription records indicating sufficient medication supply between visits.

*dCompliance rate was measured according to the percentage of patients who took medication during the study period; if the rate was > 80%, compliance was considered good and if < 80%, it was considered poor.
in people with T2DM suggest comparable effectiveness.54 One study even demonstrated better response with NTX/BPN in people with T2DM versus those without T2DM, although the statistical significance was borderline. On one hand, it is likely that these real-world studies do not adequately control for unmeasured confounding factors; for example, it is possible that people with T2DM selected for treatment with NTX/BPN had a more hedonic phenotype (e.g., reward-based eating behaviors) that could have made this cohort more responsive to this treatment compared with people without T2DM. The included studies also did not test the relative effectiveness of different agents in people with T2DM and, therefore, conclusions cannot be drawn on whether a particular AOM, such as NTX/BPN, is more effective than current preferred agents (e.g., glucagon-like peptide-1 receptor agonists) in this population. On the other hand, the demonstrable effectiveness in these real-world studies confirms the feasibility of weight loss success with AOMs generally in people with T2DM despite the known greater resistance to weight loss in this population.54

Weight regain or inadequate weight loss after bariatric surgery is challenging to manage since these patients have already undergone the gold-standard treatment modality for obesity. Furthermore, these patients likely represent a distinct group of individuals with different background characteristics compared with the general obesity population. The RWE studies identified in this review indicate that AOMs may be a viable adjunctive treatment option for certain postsurgical patients.19,20,49-53 Findings from real-world practice also suggest that AOMs could have varying effects depending on type of metabolic surgery,19,20,50 which may be due to the interplay between different surgical procedures and drug mechanism of action. These studies were also mostly conducted in specialized weight management centers, underscoring that, at present, AOMs are not routinely prescribed after surgery except in obesity centers with expertise in managing such patients.

Taken together, the data across studies suggest that AOMs are well tolerated in real-world practice. AE severity was infrequently reported, but where details were given, it was generally noted that AEs appeared to be mild to moderate in severity and were mostly short-lived. However, in some studies, AEs constituted one of the main reasons for discontinuation. Although the reason for this disconnect is not completely clear and the severity of AEs leading to discontinuation is not specified in the included studies, it is possible that healthcare providers and/or patients have a lower threshold for tolerating AEs in the real world compared to clinical trials. Historically, the medical management of obesity has been perceived as an elective option, providers have not received formal training in obesity management, and those who prescribe AOMs have faced judgment and stigma from peers. Collectively, these factors may lower provider tolerance for AEs or limit their confidence in managing mild to moderate AEs in clinical practice. Patients in the real world may also present with more multi-morbidity and clinical complexity compared with those in clinical trials, and that too may lower the tolerance for mild to moderate AEs and lead to more discontinuation of AOMs.

Adherence and persistence are important determinants of AOM effectiveness, and it is known that weight loss is not typically sustained upon cessation of therapy.32 Again, wide variations were observed in reporting methods and presentation of compliance results across studies, but generally, adherence and persistence with AOMs in clinical practice appeared to be poor. No conclusive evidence could be drawn regarding superiority of one AOM over another with respect to compliance due to the limited number of comparative studies identified. However, adherence and persistence with liraglutide appeared to be higher than orlistat in an unadjusted (but not adjusted) analysis in one study, and higher than NTX/BPN and PHEN/TPM in another.31,32 There was also the suggestion that PHEN/TPM may be associated with better adherence and persistence versus other AOMs, except liraglutide.31,33 Overall, the field would benefit from agreed standards to measure these compliance outcomes to allow for comparability across studies.

The reasons underlying poor compliance are likely to be multifactorial and could include variable weight-loss efficacy or perceived ineffectiveness, intolerable AEs, drug costs, inadequate healthcare provider training, and lack of patient education.19,20,22,44 Many patients may have unrealistic expectations regarding the extent of weight loss that can be achieved with their medication and become discouraged early in therapy if the results are not as dramatic as they hoped.31 Both providers and patients also tend to view AOMs as a jump start for weight loss rather than chronic therapy that extends to weight maintenance, and this may account for lack of persistence even in those who initially achieve meaningful weight loss. Since the benefits of short-term weight loss are unclear, low compliance with AOMs raises important questions regarding the cost-effectiveness or value of the treatment as it is currently applied in the real world. Low persistence and adherence will need to be addressed to sustain the observed real-world effectiveness of AOMs and achieve the potential long-term benefits of AOM-induced weight loss.

Real-world data are emerging as an important component of the overall evidence base for understanding the utility of medications across a range of patient populations.52 These data may represent a valuable supplement to those obtained in RCTs. For example, sibutramine was withdrawn from global markets due to CV safety concerns reported in RCTs.55 Real-world studies failed to demonstrate such CV risks in a more generalizable patient population, suggesting that the marketing authorization for sibutramine may have been inappropriately withdrawn for patients without pre-existing CV disease.13,56,57

More studies identified by the current search were conducted in secondary/tertiary care compared with primary care settings. However, as obesity rates continue to climb and its acknowledgment as a chronic disease continues to grow, more and more individuals will seek weight management advice from their primary care physician. Therefore, it is important to gain a better understanding of the experience of patients in this setting. The fact that 12 primary care studies were identified by this review suggests that AOMs are effective and well tolerated in this setting. These studies provide valuable information regarding the translation of obesity management from the
One of the challenges with RWE is the difficulty in interpreting data across studies. Methods, populations, data collection, and reporting vary considerably from one evaluation to the next. In addition, confounding by background lifestyle measures is a major issue. Clinical guidelines for obesity management and label indications for FDA-approved AOMs specify that pharmacotherapy for obesity only be used as an adjunct to lifestyle modification, where such modification is subject to varied interpretation. This requirement means that measurement of the true efficacy of an individual AOM alone is rarely, if ever, achieved. Certainly, a range of adjunct lifestyle measures—including calorie-deficit diets, nutritional counseling, physical activity recommendations, and/or intensive behavioral therapy—have been adopted as part of the study design in RCTs evaluating AOMs. Since there is limited objective assessment of adherence to such recommendations in these trials, adjunct lifestyle measures can be viewed as a major source of confounding. Similarly, the findings from this review indicate that participants in real-world studies may be enrolled in rigorous weight-management programs or following specific dietary restrictions and programs of physical activity. However, the capture of this information is variable and adherence to such measures is seldom reported. This contributes to the heterogeneity among real-world studies, making it difficult to summarize weight-loss effects of a single drug, let alone compare effects across different medications. In the absence of appropriate control arms in real-world studies, the interaction between AOM and lifestyle measures is unclear. In a similar way, it is difficult to appreciate the real-world impact of AOMs in the studies including people with T2DM because few of these provided details of any concomitant glucose-lowering medications. Since many of these agents also promote weight gain or weight loss, they could have an impact on AOM effectiveness in these patients that confounds the results.

The current review is subject to several limitations that relate to the search itself, the evidence base, and issues inherent in the methods of real-world studies. While the search was conducted using a robust and reproducible protocol, the approach was largely pragmatic, and it cannot be ruled out that other studies relevant to the research question may have been published. The research question focused on specific FDA-approved AOMs deemed to be relevant to the current pharmacologic management of obesity. As such, studies that provided RWE for the effectiveness of AOMs generally without specific drug-level data were not a part of the search strategy. In addition, a two-stage approach was adopted for the review of search results; at the first stage, the decision to include or exclude a publication is made based on review of the title/abstract and not on a comprehensive review of the full-text of the article, so it is possible that potentially relevant studies are excluded at this stage due to lack of detail in the title or abstract. For example, if the AOMs of interest were not specifically mentioned by name in the title/abstract, the study did not meet our eligibility criteria, but it could be that the full-text of the publication did provide disaggregated data on that agent. Furthermore, inconsistencies in the description of RWE in the literature, the range of terminologies used, and the lack of clarity in methods for data collection—even in the full-text of some papers—made the decision to include challenging in some cases. The reviewers were also compelled to exercise a level of value judgement as to whether a study truly reflected real-world practice. For example, some studies—though conducted in a clinical setting and termed observational—had strict inclusion/exclusion criteria, highly prescriptive scheduling and conduct of clinic visits, and did not appear to fully reflect patient behaviors were they not to have been included in the study. In such cases, the studies were extensively discussed among reviewers until consensus was met.

While the search was designed to identify a wide array of outcomes associated with AOMs, substantial gaps were evident in the RWE. Few studies were identified that reported data on outcomes other than weight change, AEs, and compliance. Data on cardiometabolic risk factors was generally limited, although this is perhaps not surprising given that healthcare providers may not routinely monitor metabolic labs in clinical practice due to the constraints of cost and insurance coverage. Only two studies each (5% of the total) were identified as including limited data on economic outcomes or patient-reported outcomes. This is also expected since routine real-world data sources like EMR or claims databases will often not capture patient-reported outcomes. There is, therefore, a need for other forms of data capture in a real-world setting (e.g., in the form of pragmatic trials) to evaluate these types of outcomes.

Another identified gap was that most studies were single arm, comparing the impact of each drug to baseline; practically none included a control arm, and relatively few studies were identified that directly compared different AOMs. Furthermore, few studies included details regarding the analytical approach for handling missing data. Since these methods can influence bias in the results, it is difficult to know if accurate conclusions about the data have been drawn in individual studies. Many of the included studies also contained small numbers of patients and were of short duration; data are, therefore, lacking on the maintenance of weight loss. Finally, selection bias is inherent in many of the studies since healthcare professionals often do not proactively address obesity with the use of AOMs, but rather patients seeking weight-loss options beyond diet and exercise request medication from their physician or self-refer to weight-management specialists. It is not known from the included studies whether physicians provided objective advice and counseling regarding AOMs when medically indicated independent of patient requests. As such, the data may not represent the real-world effectiveness of AOMs in the indicated population, but rather in a subset of patients who may have proactively requested this treatment option.

5 | CONCLUSIONS

RWE for the effectiveness and safety of AOMs were identified in a diverse obesity population. Such evidence can supplement the findings previously reported in tightly controlled RCT patient samples. Across studies employing prospective and retrospective designs, AOMs were consistently demonstrated to reduce weight in a general
population of patients with obesity/overweight, in patients who had regained weight or experienced inadequate weight loss after bariatric surgery, and in specific patient subgroups such as T2DM. Weight loss was often accompanied by positive changes in other cardiometabolic risk factors, when measured. Although AOMs were well tolerated in real-world studies with mostly mild to moderate AEs, a general pattern of poor compliance was apparent with all treatments, the reasons for which will need to be better understood and addressed to fully evaluate the long-term benefit of AOMs in the real world.

Importantly, the review identified large gaps in the evidence base for AOMs in treating patients with obesity or overweight in real-world practice, including few comparative effectiveness studies and a narrow range of reported outcomes. Real-world studies are also affected by the same issues that plague RCTs in the obesity field with respect to untangling the interactions between adjunct lifestyle measures and AOMs. There is a clear need for more extensive and consistently designed real-world studies, including pragmatic trials, that incorporate valid control and/or comparator groups, that examine more recently approved medications, and that more robustly account for the relative contributions of lifestyle interventions. Such studies can capture a broader range of outcomes, including cardiometabolic, economic, and patient-reported measures. Strengthening the approach to RWE generation in obesity will help build a more accurate picture of the value of AOMs in routine clinical practice, especially as newer agents promising greater efficacy are on the horizon.

ACKNOWLEDGMENTS

The authors thank Kimberly Gudzune of Johns Hopkins University (Baltimore, MD, USA) for her critical appraisal of the manuscript. They also thank Mick Arber (York Health Economic Consortium [YHEC]) for assistance with the literature search, and Alison Terry of KMHO Ltd (Brighton, UK) for assistance with editing of the manuscript, which was funded by Eli Lilly and Company (Indianapolis, IN, USA).

This research was funded by Eli Lilly and Company (Indianapolis, IN, USA).

CONFLICT OF INTEREST

N.N.A., J.L.P., and H.K. are full-time employees and shareholders of Eli Lilly and Company (Lilly). S.R. and T.K.-M. are employees of KMHO and received funding from Lilly for time spent conducting this research. Lilly and authors employed by Lilly are involved in obesity drug research.

ORCID

Hong Kan https://orcid.org/0000-0002-4585-5016

REFERENCES

1. World Health Organization (WHO). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Global Burden of Disease (GBD) 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13-27.
3. Tremmel M, Gerdhthem UG, Nilsson PM, Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017;14:435.
4. Organisation for Economic Co-operation and Development (OECD). The Heavy Burden of Obesity: The Economics of Prevention. OECD Health Policy Studies. Paris: OECD Publishing; 2019.
5. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. PharmacoEconomics. 2015;33:707-722.
6. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82:2225-2255.
7. DeMaria E, English WJ, Mattar SG, Brethauer SA, Hutter M, Morton JM. State variation in obesity, bariatric surgery, and economic ranks: a tale of two Americas. Surg Obes Relat Dis. 2018;14(11 suppl):S71.
8. Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care: a systematic overview of international evidence-based guidelines. Obes Rev. 2019;20:1218-1230.
9. Williams DM, Nawaz A, Evans M. Drug therapy in obesity; a review of current and emerging treatments. Diabetes Ther. 2020;11:1199-1216.
10. Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Anti-obesity medication use in 2.2 million adults across 8 large healthcare organizations: 2009–2015. Obesity (Silver Spring). 2019;27:1975-1981.
11. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. Jama. 2018;320:1172-1191.
12. Blonde LA-O, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763-1774.
13. Hayes JF, Bhaskaran K, Batterham R, Smeth L, Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes (Lond). 2015;39(9):1359-1364.
14. Hollywood A, Ogden J. Taking orlistat: Predicting weight loss over 6 months. J Obes. 2011;2011:806896.
15. Kim HO, Lee JA, Suh HW, et al. Postmarketing surveillance study of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin. 2005;21(11):1885-1890.
16. Schwartz SM, Bansal VP, Hale C, Rossi M, Engle JP. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting. Obes Surg. 2008;26:452-458.
17. Sulliman M, Buckley A, Al Tikriti A, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in nonsurgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498-1501.
18. Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen R. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9:e12323.
19. Aagaard L, Hallgreen CE, Hansen EH. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. Int J Obes (Lond). 2016;40(11):1742-1747.
20. Acharya NV, Wilton LV, Shakir SA. Safety profile of orlistat: results of a prescription-event monitoring study. Int J Obes (Lond). 2006;30(11):1645-1652.
21. Ahn SM, Kim H, Ji E, Han N, Oh JM. The effect of orlistat on weight reduction in obese and overweight Korean patients. Arch Pharm Res. 2014;37(4):512-519.
24. Allie EC, Kane MP, Busch RS, Bakst G, Hamilton RA. Orlistat in obese patients with type 2 diabetes: a retrospective assessment of weight loss and metabolic effects. *Hosp Pharm.* 2004;39:37-42.

25. Beermann B, Melander H, Säwe J, Ullerød C, Dahlqvist R. Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. A cohort study. *Eur J Clin Pharmacol.* 2001;57(4):309-311.

26. Costello T, Dorrell M, Kellams T, Kraska K. Review of pharmacologic weight loss medications in a patient-centered medical home. *J Pharm Technol.* 2016;32(1):37-41.

27. Czerneckow S, Knol MJ, Fezeu L, Grobbee DE. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study. *Eur J Prev Cardiol.* 2012;19(3):484-489.

28. Derby LE, Myers MW, Jick H. Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. *Br J Clin Pharmacol.* 1999;47(5):565-569.

29. Douglas IJ, Bhaskaran K, Batterham RL, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case study in UK clinical practice research datalink. *BMJ.* 2013;346(jul12 1):f1936.

30. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. *Br J Clin Pharmacol.* 2015;79(6):1020-1027.

31. Ganguly R, Tian Y, Kong SX, et al. Persistence of newer anti-obesity medications in a real-world setting. *Diabetes Res Clin Pract.* 2018;143:348-356.

32. Gorgojo-Martínez JA-O, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. *Int J Clin Pract.* 2019;73:e13399.

33. Grabarczyk TR. Observational comparative effectiveness of pharmaceutical treatments for obesity within the Veterans Health Administration. *Pharmacotherapy.* 2018;38(1):19-28.

34. Graham MR, Landgraf CG, Lindsey CC. A comparison of orlistat use in a veteran population: a pharmacist-managed pharmaceutical therapy weight-loss clinic versus standard medical care. *J Pharm Technol.* 2003;19:343-348.

35. Hemo B, Endevetel R, Porath A, Stampfer MJ, Shai I. Adherence to weight loss medications: post-marketing study from HMO pharmacy data of one million individuals. *Diabetes Res Clin Pract.* 2011;92:269-275.

36. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. *Obesity.* 2011;19(12):2351-2360.

37. Hong JL, Meier CR, Sandler RS, Jick SS, Stürmer T. Risk of colorectal cancer after initiation of orlistat: matched cohort study. *BMJ.* 2013;347(aug27 2):f5039.

38. Horie NC, Cercato C, Mancini MC, Halpern A. Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic. *Drugs Aging.* 2010;27(6):497-506.

39. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. *N Engl J Med.* 1998;339(11):719-724.

40. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. *Obesity.* 2019;27(4):591-602.

41. Li Z, Hong K, Yip I, et al. Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study. *Curr Ther Res Clin Exp.* 2003;64(7):447-460.

42. Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Piroetto J. Combination phentermine and topiramate for weight maintenance: the first Australian experience. *Med J Aust.* 2014;201(4):224-226.

43. Padwal R, Kezouh A, Levine M, Etmiman M. Long-term persistence with orlistat and sibutramine in a population-based cohort. *Int J Obes (Lond).* 2007;31(10):1567-1570.

44. Perrio MJ, Wilton LV, Shakir SAW. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. *Obesity.* 2007;15(11):2712-2722.

45. Poongodi A, Parthiban L. Analysis of adverse reaction associated with dietary drug orlistat using data mining algorithms. *Int J Pharm BioSci.* 2017;8:P74-P80.

46. Ritchey ME, Harding A, Hunter S, et al. Cardiovascular safety during and after use of phentermine and topiramate. *J Clin Endocrinol Metab.* 2019;104(2):513-522.

47. Shibuya K, Ali KF, Ji X, et al. The benefit of short-term weight loss with anti-obesity medications in real-world clinical practice. *Endocr Pract.* 2019;25:1022-1208.

48. Wharton S, Liu A, Pakeresht A, et al. Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. *Obesity.* 2019;27(6):917-924.

49. Elhag W, El Ansari W, Razaq S, Elsherif M, Mustafa I. Lorcaserin vs. phentermine among non-surgical and surgical obese patients: anthropometric, glycemic, lipid, safety and cost outcomes. *Ann Med Surg.* 2019;45:75-81.

50. Nor Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. *Surg Obes Relat Dis.* 2018;14:93-98.

51. Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. *Obes Surg.* 2018;28:3553-3558.

52. Schwartz J, Chaudhry UL, Suzo A, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight reduction or weight loss plateau post-bariatric surgery: a retrospective review. *Obes Surg.* 2016;26(2):452-458.

53. Toth AT, Gomez G, Shukla AP, et al. Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. *Children (Basel).* 2018;5:116.

54. Kahan S, Fujioka K. Obesity pharmacotherapy in patients with type 2 diabetes. *Diabetes Spectr.* 2017;30:250-257.

55. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med.* 2010;362:905-917.

56. Harrison-Woolrych M, Ashton J, Herbsnon P, Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. *Drug Saf.* 2010;33:605-613.

57. Tyczynski JE, Oleske DM, Klingman D, Ferrufino CP, Lee WC, Antel J. Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study. *Drug Saf.* 2012;35:629-644.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Ahmad NN, Robinson S, Kennedy-Martin T, Poon JL, Kan H. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review. *Obesity Reviews.* 2021;22(11):e13326. https://doi.org/10.1111/obr.13326